Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines
Atommap Corporation
Fathom Therapeutics, formerly Atommap Corp., a company that uses quantum chemistry and AI to design novel drug molecules by predicting their behavior inside living cells, today announced an oversubscribed $47 million Series A financing.